Vitamin D Levels and Survival in Cancer Patients

NCT03266887 | Completed

• 1 other identifier: HI14010102
• Study Type: observational
• Target: 5,764
• Locations: 0 countries
• Sites: N/A

Brief Summary

Using the population-based data sources in Iceland and the well-characterized AGES-Reykjavik cohort, our overarching aims are on exploring whether pre-diagnostic serum levels of 25-hydroxyvitamin D (25(OH)D) among older individuals living in Iceland were associated with survival after cancer diagnosis. We also wanted to assess the risk of being diagnosed with cancer in association with 25(OH)D levels. In this population living just south of the arctic circle, vitamin D levels largely depend on dietary- and supplemental sources.

Conditions

Neoplasms

Outcome Measures

Primary Outcomes (1)

• Overall mortality among cancer patients

  We tested the association between pre-diagnostic 25(OH)D levels and total survival

  Patients were followed from date of diagnosis since 2002 until death or censored at end of the follow-up (December 31, 2014)

Secondary Outcomes (1)

• Cancer-specific mortality among cancer patients

  Patients were followed from date of diagnosis since 2002 until death or censored at end of the follow-up (December 31, 2014)

Other Outcomes (1)

• Pre-diagnostic 25(OH)D levels and cancer risk

  Participants without cancer were followed from the study entry since 2002 until cancer diagnosis, death or end of the observation period whichever occurred first (December 31, 2014)

Eligibility Criteria

• Age: 66 Years - 98 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

In 1967, all 30,795 men and women living in the capital area of Iceland and born between 1907 and 1935 were invited by the Icelandic Heart Association to join a prospective cohort study. Approximately 19,000 attended the clinic at least once and became participants of the Reykjavik Study. Subsequently, in 2002, a random sample of the cohort comprising 5,764 men and women who were still alive in Iceland and aged 66 to 96 years entered the Ages Gene/Environment Susceptibility (AGES) - Reykjavik Study (20). Serum 25(OH)D was measured in 5,519 of all 5,764 (96%) participants at study entry in year 2002 through 2006.

You may qualify if:

• To be part of the AGES-Reykjavik Study, initiated between 2002 and 2006.

You may not qualify if:

• Diagnosed with cancer at study entry

Sponsors & Collaborators

• Icelandic Heart Association: lead
• University of Iceland: collaborator

Related Links

• Age, Gene/Environment Susceptibility-Reykjavik Study: Multidisciplinary Applied Phenomics

Biospecimen

Retention: SAMPLES WITH DNA

Serum

MeSH Terms

Conditions

Neoplasms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2017
• First Posted: August 30, 2017
• Study Start: January 1, 2002
• Primary Completion: December 30, 2006
• Study Completion: December 30, 2006
• Last Updated: August 30, 2017

Record last verified: 2017-08